Oral Solid Dosage Manufacturing: Inside Rottendorf Pharma’s Strategic Alliance With Corealis Pharma
From PharmaSource Podcast by Life Science Networks
April 23, 2026 · 23 min
About this episode
Eike Cordts discusses the strategic alliance between Rottendorf Pharma and Corealis Pharma and its implications for pharmaceutical development.
“Aligning development strategy early creates a real competitive advantage. When scalability and late-stage requirements are already considered during Phase I and II, you avoid gaps that cause delays further down the line.” Eike Cordts, Director Early Stage Development USA, Rottendorf Pharma, leads early stage development initiatives in North America for Rottendorf Pharma, a German CDMO with nearly a century of expertise in oral solid dosage (OSD) forms. Having grown from 800 to over 1,400 employees in the past decade, Rottendorf Pharma recently formalized a strategic transatlantic partnership with Corealis Pharma, a Canadian early-phase OSD specialist. In this PharmaSource podcast episode, Eike explains the strategic thinking behind the alliance and what it means for pharmaceutical companies seeking an integrated development-to-commercialization pathway. Read more .
People in this episode
Guest: Eike Cordts
Topics covered
- oral solid dosage
- pharmaceutical development
- strategic alliances
- early stage development
- commercialization pathways
Keywords
- Rottendorf Pharma
- Corealis Pharma
- oral solid dosage
- development strategy
- pharmaceutical companies
- transatlantic partnership
- scalability
- commercialization
Mentioned in this episode
Organizations: Rottendorf Pharma, Corealis Pharma
Places: North America, Germany, Canada
More episodes of PharmaSource Podcast
- How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar · June 11, 2026 · 31 min
- The Politics Behind the Pipeline: How MFN Pricing and Tariffs Are Reshaping Pharma's Global Strategy · June 8, 2026 · 18 min
- How to Build a Resilient Global Vaccine Supply Chain: From Crisis to Capability · June 4, 2026 · 46 min
- How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization · May 31, 2026 · 29 min
- The Strategic Partnership Gap: Why CDMOs Are Meeting Pharma's Expectations Less Than Half the Time with Simon-Kucher · May 27, 2026 · 26 min
- Creative Financing Strategies for Biotech's Bear Market, Beyond the VC Round · May 25, 2026 · 29 min
Explore listener stats, chart rankings, contacts and more on the PharmaSource Podcast podcast page.